Phase III, randomised trial of avelumab versus physician’s choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300
Yu Jeong Bang(Seoul National University), Eduardo Yañez Ruiz(Universidad de La Frontera), Eric Van Cutsem(KU Leuven), Kuhn‐Uk Lee(Seoul National University Bundang Hospital), Lucjan Wyrwicz(The Maria Sklodowska-Curie National Research Institute of Oncology), Michael Schenker, María Alsina(Vall d'Hebron Institute of Oncology), Min‐Hee Ryu(Ulsan College), Hyun Cheol Chung(Yonsei University Health System), Ludovic Evesque(Centre Antoine Lacassagne), Salah-Eddin Al-Batran(Krankenhaus Nordwest), Se Hoon Park(Samsung Medical Center), M. Lichinitser, Narikazu Boku(National Cancer Center Hospital East), Markus Moehler(Johannes Gutenberg University Mainz), Janet Hong(Ono Pharmaceutical (United States)), Hua Xiong(Ono Pharmaceutical (United States)), Roland Hallwachs(Merck (Germany)), Ilaria Conti(Ono Pharmaceutical (United States)), Julien Taı̈eb(Sorbonne Université)
Cited by 503Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis